As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
19 Analysts have issued a Cogent Biosciences Inc forecast:
19 Analysts have issued a Cogent Biosciences Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -297 -297 |
23%
23%
|
|
| EBIT (Operating Income) EBIT | -300 -300 |
23%
23%
|
|
| Net Profit | -204 -204 |
5%
5%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Andrew Robbins |
| Employees | 205 |
| Founded | 2014 |
| Website | www.cogentbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


